Production Of GSK's Ziagen HIV Oral Liquid Medicine

GlaxoSmithKline Canada Inc. employees package bottles of Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images